SEC 13F Intelligence

Kinnevik AB (Publ) / RXRX

Kinnevik AB (Publ)’s Recursion Pharmaceuticals In Position

Does Kinnevik AB (Publ) own Recursion Pharmaceuticals In (RXRX)? Yes — 13.43M shares worth $66M (+100.00% of its 13F portfolio) as of Q3 2025.

Position Value
$66M
Q3 2025
Shares
13.43M
% of Portfolio
+100.00%
Quarters Held
12
currently held

Position History RXRX

Reported value by quarter
Q4 ’22: $59MQ4 ’22Q1 ’23: $51MQ2 ’23: $78MQ2 ’23Q3 ’23: $80MQ4 ’23: $103MQ4 ’23Q1 ’24: $104MQ2 ’24: $89MQ2 ’24Q3 ’24: $78MQ4 ’24: $80MQ4 ’24Q1 ’25: $71MQ2 ’25: $68MQ2 ’25Q3 ’25: $66Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q3 202513.43M$66M+100.00%
Q2 202513.43M$68M+100.00%
Q1 202513.43M$71M+100.00%
Q4 202411.91M$80M+100.00%
Q3 202411.91M$78M+100.00%
Q2 202411.91M$89M+100.00%
Q1 202410.41M$104M+100.00%
Q4 202310.41M$103M+100.00%
Q3 202310.41M$80M+100.00%
Q2 202310.41M$78M+100.00%
Q1 20237.65M$51M+68.47%
Q4 20227.65M$59M+33.28%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Kinnevik AB (Publ)’s full portfolio or all institutional holders of RXRX.